Attached files
| file | filename |
|---|---|
| 10-K - Qualigen Therapeutics, Inc. | form10-k.htm |
| EX-32.1 - Qualigen Therapeutics, Inc. | ex32-1.htm |
| EX-31.2 - Qualigen Therapeutics, Inc. | ex31-2.htm |
| EX-31.1 - Qualigen Therapeutics, Inc. | ex31-1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
As independent registered public accountants, we hereby consent to the incorporation by reference in Registration Statement Nos. 333-215143, 333-202924 and 333-208818 of Ritter Pharmaceuticals, Inc. on Form S-l, Registration Statement No. 333-213087 on Form S-3, and Registration Statement Nos. 333-212062 and 333-207709 on Form S-8 pertaining to the 2008 Stock Plan, 2009 Stock Plan, and 2015 Equity Incentive Plan of Ritter Pharmaceuticals, Inc. of our report dated February 27, 2017, with respect to the financial statements of Ritter Pharmaceuticals, Inc. (which report includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern) for each of the years in the two year period ended December 31,2016, included in this annual report on Form 10-K of Ritter Pharmaceuticals, Inc. for the year ended December 31, 2016.
Orange County, California
February 27, 2017